Good morning, everyone. Hilde Steineger, CEO of Cantargia. Cantargia is a listed company, so this is our forward-looking statement. Cantargia is the prominent IL1RAP company. So far, we are the first company to have developed drugs against IL1RAP, and also the first company that has been able to develop two clinical candidates generated so far by our target and our library. The library is growing. We now have 500 clones targeted against IL1RAP that we use to develop new antibodies for bispecific or ADCs, but also for analytical purposes. We have not only generated two clinical candidates, but we have also been able to monetize on this target. We made a deal, as you probably are aware, with Otsuka last summer, and the total bio dollar deal was $613 million with a $33 million upfront.
Inflammatory diseases drive serious disease, and even though they are serious, the targets and the drugs remain poorly drugged. The challenge has never been to find a good target, but it is finding the right target and drug in a block the right way. We believe that if you block too narrow, the disease tends to find a way around the blockage, while if you block too broad, you risk taking the patient's immune system down with you. The IL1RAP for us is the perfect way of addressing this exact point. IL1RAP, interleukin-1 receptor accessory protein, is a co-receptor that binds together with three other interleukin receptors, IL-1, 33, and 36. The fact that one intervention can bind and block three inflammatory pathways makes this target very versatile.
We have used that component for making programs and drugs for inflammatory diseases and oncology diseases, and I will walk you through many of those initiatives in the coming slides. Our key asset is nadunolimab, and we have programs both targeting pancreatic cancer and leukemic diseases. The leukemic disease, we had a press release yesterday, and I will walk you through the results. It is an investigator-initiated trial sponsored by MD Anderson and the Department of Defense in the U.S. We also have a very interesting autoimmune program where CAN10 is our lead asset, and which is now in the very capable hands of Otsuka Pharmaceutical. Building on the knowledge that we acquired developing CAN10, we have now also developed a bispecific antibody where one target of the bispecific is IL1RAP, and we will disclose the target for the second target closer to Christmas this year.
Our management team is very experienced and comes from both big pharma and big biotech. We were also recently so lucky to be able to attract Monic Stuart, who is a licensed hematologist and has also long-standing experience in clinical development from Genentech, Geron, and Revolution Medicines. She is complementing our team in an excellent way. Now, let us turn to myeloid malignancies, more specifically MDS and AML. Nadunolimab targets the cells that chemotherapy leaves behind. Leukemic stem cells, they survive chemotherapy and leaves the leukemic stem cells as a reservoir to seed further progression of the disease. So by having a target that targets only the leukemic stem cells, but leaves the normal hematopoietic stem cells alone, is an excellent way to treat this patient population. Now, leukemic stem cells survive and thrive by signaling of interleukin-1, both alpha and beta.
By blocking interleukin-1, we are then preventing the survival of the leukemic stem cells. Nadunolimab also has a dual mode of action where it targets the cells for killing by your natural immune defense. Again, it only targets the leukemic cells and not the normal hematopoietic stem cells. With this dual action, we are able to kill the malignant cells, but have a healthy reservoir available for recovery. Yesterday, we announced that the embargo of the ASH abstract submitted by MD Anderson was lifted. In this abstract, we and MD Anderson could show that of the 10 patients that we evaluated in the MDS group, seven out of 10 responded. The data cut was in June, and we also, in this data cut, we saw a 33% response rate in the AML group, which is a very hard-to-treat patient population.
A 33% response rate is both clinically relevant, but also a significant finding. The phase I-B part of this phase I-B/II-A has now finished, and safety looks excellent. There was only one adverse event with a grade three or four reported, likely related to nadunolimab treatment, and that was an infusion reaction. It was not a super complicated adverse event to manage. The next steps in the development will be that there is an oral presentation of our abstract. All abstract that is sent to ASH, of the many that is sent, few are then chosen to be an oral presentation. For us, this is a recognition of the data quality and the data importance, that it was chosen to be an oral presentation at ASH. We will continue, or MD Anderson will continue to enroll patients, and the plan is to enroll approximately 40 patients.
Turning to pancreatic ductal adenocarcinoma, or PDAC. PDAC remains a deadly disease with limited treatment options. However, daraxonrasib, or RASONQUE, was approved for treatment in second line in August this year. That has created a new starting point for the whole field, meaning that second line will always include now daraxonrasib. That is standard of care. First line, however, remains chemotherapy. For us, embarking of a combination study with daraxonrasib is an important step because we have already shown excellent clinical results in combination with chemotherapy, 13.2 in the overall population, 13.2 months overall survival, compared to six to seven months in chemotherapy alone. That was our previous result, and now having embarked on phase I-B with daraxonrasib opens up a lot of opportunities for nadunolimab to be combined with either daraxonrasib or GnP. There we go.
The combination study makes sense from a new starting point of standard of care. However, it also makes excellent sense scientifically. Daraxonrasib hits the tumor cells through the RAS inhibition of its signaling pathways. However, the tumor microenvironment remains the same. The shielding the tumor and the tumor growth is not affected by daraxonrasib. In addition, we know that resistance does exist and will follow the treatment. These patients eventually die, and what has been shown in the RASolute 302 study was that 41% of patients after six months progress, and after 12 months, almost all of the patients have progressed. If you combine daraxonrasib with nadunolimab, we will have a double hit on the tumor, and the reason for that is that we do not hit the same pathways. Daraxonrasib hits the RAS inhibition pathway, while we hit with blocking of interleukin-1, the interleukin pathways.
What we do see in addition to the double hit is that we have a breakdown of the tumor microenvironment. In our preclinical models, we have seen that not only that we can break the tumor microenvironment and the shield around the tumor, but also that the T cells and NK cells move back in, helping the tumor and helping the body to recover from this tumor invasion. This combination has only, or by only the combination, we see both the microenvironment disappearing and the return of the immune cells, so you need both components to see this effect. We are again embarking on a phase I-B study where we will study first of all the safety and bioavailability in the combination. We will recruit approximately 15 patients that have progressed on first-line standard of care. We are targeting to initiate the study in Q1 next year.
Sorry. I will have to interrupt you.
Okay. I will be quick.
Yep.
The next milestone of the three pillars that we have, the next year and a half will be an exciting time for Cantargia. We will have the ASH presentation in December. We will have also the second targets announced closer to Christmas. We will embark on the first phase I-B combination trial with daraxonrasib. In addition, we will get in mid-2027 our high-level results from the phase II-A study in MDS and AML.
Thank you, Hilde.
Thank you.
Do we have any questions from the audience? I wanted to ask you then about the results that you released yesterday.
Yeah
Maybe a comparison between that and the standard of care.
Yeah. Standard of care is hypomethylating agents, azacitidine, and especially in MDS, 30% of the patients there progress within 6-12 months. The response rate there, depending on the age range, is around 10%-30%. The 70% response rate that we have is meaningful. However, it is few patients, and we don't have the durability of effect yet. We're looking forward to more data.
And you mentioned these patients, we're talking very seriously ill patients in-
Yeah
-both AML and
Yeah, especially the relapsed/refractory patients in AML. They normally don't survive more than up to three to six months. Very hard to treat, and when they have relapsed like we have, normally nothing works. Having even one complete response as we have in nine patients is a meaningful result.
Of course. Thank you so much, Hilde.
Thank you.